Crohn's disease trials in France

In France 82 Also abroad 422

82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Amiens Cedex 1, Besançon, Clichy, Creteil Cedex, Dijon, Échirolles, Le Kremlin-Bicetre, Lille Cedex, Marseille, Nantes, Neuilly-Sur-Seine, Nice, Nimes Cedex 9, Paris, Pierre-Bénite, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Amiens Cedex 1, Besancon Cedex, Clichy, Creteil, Dijon, Échirolles, Le Kremlin-Bicetre, Lille Cedex, Marseille, Montpellier Cedex 5, Nantes, Neuilly-Sur-Seine, Nice, Nimes Cedex 9, Paris, Pessac, Pierre-Bénite, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Where
Lille Cedex, Neuilly-Sur-Seine, Nice, Vandoeuvre Les Nancy
Age
18 years and over
People
1,380 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00
No phaseTaking people
Ibd CAncer and seRious Infections in France (I-CARE 2)
Where
Amiens, Paris
Age
18 years to 75 years
People
6,000
Run by
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
See details and how to joinNCT06089590
No phaseTaking people
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Where
Amiens, Besançon
Age
18 years and over
People
800
Run by
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
See details and how to joinNCT07719426
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Pierre-Bénite, Saint-Priest-en-Jarez, Vandoeuvre Les Nancy
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Échirolles, La Roche-sur-Yon, Le Kremlin-Bicêtre, Montpellier, Neuilly-sur-Seine, Nice, Paris, Rouen, Saint-Priest-en-Jarez, Toulouse
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 4Taking people
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Where
Amiens, Besançon Cedex, Brest, Caen Cedex 9, Clermont-Ferrand cedex, Créteil, Lille Cedex, Nice, Nîmes, Paris, Poitiers, Toulouse cedex 9, Valence
Age
18 years to 75 years
People
75
Run by
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
See details and how to joinNCT07292012 · EU 2025-521889-95-00
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Amiens Cedex 1, Lille Cedex, Paris
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Lille Cedex
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Bayonne, Clermont-Ferrand, Creteil, Échirolles, Lille, Montfermeil, Montpellier Cedex 5, Nancy Cedex, Nantes, Nice, Paris, Pierre-Bénite, Saint-Priest-en-Jarez, Toulouse Cedex 9
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Amiens, Clermont-Ferrand, Échirolles, Marseille, Nantes, Neuilly-sur-Seine, Nîmes, Paris, Pierre-Bénite, Reims, Vandœuvre-lès-Nancy
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Amiens Cedex 1, Besancon Cedex, Clichy, Creteil, Le Kremlin-Bicetre, Lille, Montpellier Cedex 5, Nancy Cedex, Nantes, Neuilly-Sur-Seine, Nice, Pessac, Pierre-Bénite, Reims Cedex, Saint-Priest-en-Jarez, Toulouse Cedex 9
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Chambray Les Tours, Clermont-Ferrand, Nancy Cedex, Neuilly-Sur-Seine, Nice, Paris Cedex 12, Saint-Priest-en-Jarez
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Montpellier Cedex 5, Nice, Saint-Priest-en-Jarez, Toulouse Cedex 9
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Chambray Les Tours, Clermont-Ferrand, Creteil Cedex, La Roche Sur Yon Cedex 9, Lille, Limoges Cedex 1, Montpellier Cedex 5, Neuilly-Sur-Seine, Paris, Pierre-Bénite, Saint-Priest-en-Jarez, Vandoeuvre Les Nancy
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Amiens, Besançon, Créteil, La Tronche, Lille, Marseille, Nantes, Nice, Paris, Saint-Etienne, Toulouse, Vandœuvre-lès-Nancy
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
No phaseTaking people
Virtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical Lesions
Where
Vandœuvre-lès-Nancy
Age
18 years and over
People
60
Run by
Central Hospital, Nancy, France
See details and how to joinNCT07413653
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Bordeaux, Bron, Paris, Toulouse Cedex 9, Tours
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Amiens Cedex 1, Marseille, Nice, Pessac Cedex, Reims Cedex, Rennes Cedex 9, Saint-Priest-en-Jarez
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 2Taking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Besançon, Clichy, Marseille, Neuilly-Sur-Seine, Paris Cedex 18, Rennes
Age
18 years and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
No phaseNot yet taking people in France
Effect of Intestinal Carriage of *Pilosibacter Rotomagensis* on Intestinal Inflammatory Activity
Where
Rouen
Age
18 years and over
People
116
Run by
University Hospital, Rouen
See details and how to joinNCT07871383
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Amiens Cedex 1, Lille Cedex, Paris
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 3Taking people
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial
Where
Amiens Cedex 1, Aurillac Cedex, Bayonne, Besancon Cedex, Caen, Clermont-Ferrand, Clichy, Colmar Cedex, Creteil Cedex, Lille, Montpellier Cedex 5, Nantes, Neuilly-Sur-Seine, Nice, Paris Cedex 10, Pessac, Pierre-Bénite, Reims Cedex, Rennes, Roubaix, Rouen Cedex, St Etienne Cedex 2, Toulon, Toulouse Cedex 9, Tourcoing Cedex, Tours, Valence, Vandoeuvre Les Nancy
Age
18 years and over
People
166
Run by
Centre Hospitalier Universitaire Amiens Picardie
See details and how to join2024-514633-38-00 · EU 2024-514633-38-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Montpellier Cedex 5, Nantes, Nice, Paris, Pessac, Pierre-Bénite, Rennes, Saint-Priest-en-Jarez, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00